THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS SUBJECT IN WHOLE OR IN PART TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN ELICERA THERAPEUTICS AB. SEE ALSO THE "IMPORTANT INFORMATION" SECTION BELOW.
Gothenburg, Sweden June 4, 2021 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immunooncological treatments focusing on CAR T cells and oncolytic viruses, announces that the subscription period for the company's new share issue prior to the scheduled listing on Nasdaq First North Growth Market ends on Tuesday June 8. In most cases, subscriptions are made earlier, for example on June 7 for subscriptions via Nordnet and Avanza.
The interest in subscribing has so far been great.
Last day for subscription of the share
Subscription is made via Nordnet and Avanza no later than Monday June 7 before the end of the day, as well as via the banks that enable their customers to subscribe in the issue. It should be noted that different banks may have an earlier day and time as the last day to register for participation in the share issue.
Decision on allotment
The decision on allocation is planned for Wednesday June 9. At the same time, the results of the issue will be announced.
Scheduled day for listing
The scheduled day for listing on Nasdaq First North Growth Market is Friday June 11.
Prospectus and more information
Complete terms and conditions for the Offer and information about Elicera can be found in the prospectus that has been published and is available on Elicera's website: https://www.elicera.com/nav/disclaimer-ipo-2021
For further information please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB
Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com
About Elicera Therapeutics AB
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses. In addition, Elicera has developed a technology platform called iTANK that can be used to optimize all CAR T cells in development and activate killer T cells against cancer.
For more information, please visit www.elicera.com
Important information
The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares or other securities in Elicera. The invitation to interested persons to subscribe for shares and warrants in Elicera will only be made through the prospectus that Elicera published May 21, 2021. No action has been, or will be taken, by Elicera to allow an offer to the public in jurisdictions other than Sweden. This press release may not be published, published or distributed, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, South Korea, Switzerland, Singapore or the United States or any other jurisdiction where such action is subject in whole or in part to legal restrictions, or would require additional prospectuses, registration or other measures than what is required by Swedish law. The information contained in this press release may also not be transmitted or reproduced in ways that are contrary to such restrictions or would entail such requirements. Measures contrary to this instruction may constitute a breach of applicable securities laws. New shares and warrants subscribed for in the Offering have not been and will not be registered under the United States Securities Act of 1933 as amended (the "Securities Act") and may not be offered, subscribed for, exercised, pledged, sold, resold, delivered or transferred, directly or indirectly, in or into the United States, except under an applicable exemption from the registration requirements of the Securities Act. The Offer is also not addressed to persons domiciled in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, South Korea, Switzerland, Singapore or in any other jurisdiction where participation would require additional prospectuses, registration or other measures than those under Swedish law.